A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy.

Trial Details

NCT ID

NCT06271837

Phase

PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Breast Cancer

Locations (sample)

Beijing, China
Beijing, China
Changchun, China
Changsha, China
Changzhou, China

Key Eligibility Criteria

At least 18 years of age.
Locally advanced, unresectable, or metastatic solid tumors based on most recent imaging.
HER2 expression.
ECOG performance status of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →